Get started

Financials · DRIO

DarioHealth Corp. (DRIO) financials

For the twelve months ended Jun 30, 2026, DarioHealth Corp. reported $21.00M of revenue and -$35.67M of net income.

Revenue, TTM
$21.00M
Revenue growth, YoY
-22.6%
Net income, TTM
-$35.67M
Net margin
-169.9%
Free cash flow, TTM
-$25.48M
Cash
$6.63M
Total debt
$31.06M
P/S
0.96
Market cap
$20.1M
Annual revenue$22.36M
FY2016FY2025
Annual net income-$41.71M
FY2016FY2025
Annual free cash flow-$26.08M
FY2016FY2025

DRIO revenue and earnings growth

DRIO revenueQ2 2026$5.18M

Quarter YoY
-3.6%
QoQ
-7.3%
FY YoY
-17.3%
5Y CAGR
+24.2%
10Y CAGR
+39.1%

DRIO revenue was $5.18M in fiscal Q2 2026 (ended Jun 30, 2026), down 3.6% from a year earlier and down 7.3% from the prior quarter. For the full fiscal 2025 it was $22.36M, down 17.3% from fiscal 2024. Compound annual growth was +24.2% over 5 years and +39.1% over 10 years. It rose in 8 of the last 10 fiscal years.

DRIO net incomeQ2 2026-$7.92M

DRIO net income was -$7.92M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$12.99M a year earlier. For the full fiscal 2025 it was -$41.71M, compared with -$42.75M in fiscal 2024.

DRIO EPSQ2 2026$0.85

DRIO diluted EPS was $0.85 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was $10.12.

DRIO free cash flowQ2 2026-$6.12M

DRIO free cash flow was -$6.12M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.08M a year earlier. For the full fiscal 2025 it was -$26.08M, compared with -$38.70M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$22.36M$27.04M$20.35M$27.66M$20.51M$7.58M$7.56M$7.39M$5.17M$2.80M
Cost of revenue$9.69M$13.77M$14.37M$18.00M$16.55M$5.06M$4.96M$5.63M$3.86M$3.36M
Gross profit$12.66M$13.27M$5.98M$9.65M$3.96M$2.51M$2.60M$1.76M$1.31M-$830.0K
Research and development$13.79M$24.18M$20.25M$19.65M$17.22M$4.43M$3.69M$3.68M$3.30M$2.15M
Selling, general and admin$15.19M$20.48M$18.14M$16.49M$23.53M$12.76M$5.48M$5.47M$4.73M$3.38M
Operating income-$36.66M-$57.74M-$56.19M-$56.81M-$76.49M-$29.90M-$17.70M-$17.69M-$14.42M-$11.10M
Interest expense$3.02M---------
Pre-tax income-$41.61M-$44.60M-$59.36M-$62.19M-$76.73M-$29.45M-$17.74M-$17.80M-$15.74M-$10.89M
Income tax$105.0K-$1.85M$64.0K$4.0K$32.0K-----
Net income-$41.71M-$42.75M-$59.43M-$62.19M-$76.76M-$29.45M-$17.74M-$17.80M-$15.74M-$10.89M
EPS, basic$10.12$12.27$38.60$50.80$81.40$80.20$160.00$312.60$656.00$836.00
EPS, diluted$10.12$12.27$38.60$50.80$81.40$80.20$160.00$312.60$656.00$836.00
Diluted shares4.0M2.5M1.4M1.2M829,585.9298,165.25113,306.7558,532.2524,070.6413,007.435

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$21.80M$27.76M$36.80M$49.47M$35.95M$28.73M$20.54M$11.13M$3.92M$1.09M
Short-term investments$4.21M-------$258.0K$225.0K
Receivables---------$0
Inventory$4.32M$4.75M$5.06M$7.96M$6.23M$2.29M$1.41M$1.38M$1.18M$888.0K
Current assets$35.07M$40.53M$47.33M$65.52M$45.60M$34.13M$22.94M$13.10M$6.05M$2.94M
Goodwill$57.43M$57.43M$41.64M$41.64M$41.64M$0----
Total assets$110.08M$118.88M$96.39M$119.19M$100.77M$35.41M$24.57M$14.09M$6.96M$3.87M
Current liabilities$9.32M$16.64M$12.49M$19.35M$14.38M$7.03M$5.22M$5.16M$3.02M$2.92M
Short-term debt-$5.45M$3.95M$8.82M$0-----
Long-term debt$30.75M$23.47M$24.59M$18.11M$0-----
Total debt$30.75M$28.92M$28.55M$26.93M$0-----
Shareholders' equity$67.92M$72.02M$58.14M$80.00M$85.55M$28.15M$18.89M$8.93M$3.94M-$6.54M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$25.94M-$38.56M-$30.38M-$47.84M-$50.41M-$17.74M-$15.72M-$11.47M-$10.62M-$8.38M
Capital expenditures$142.0K$138.0K$584.0K$442.0K$261.0K$118.0K$98.0K$71.0K$195.0K$808.0K
Free cash flow-$26.08M-$38.70M-$30.96M-$48.29M-$50.67M-$17.85M-$15.82M-$11.54M-$10.81M-$9.19M
Investing cash flow-$4.34M-$8.93M-$547.0K-$573.0K-$8.13M-$1.62M-$113.0K-$72.0K-$219.0K-$947.0K
Financing cash flow$24.31M$38.53M$18.25M$61.94M$65.77M$27.55M$25.25M$18.74M$13.46M$7.75M
Share repurchases---$134.0K------
Stock-based compensation-$46.0K--------

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-17.3%32.9%-26.4%34.8%170.8%0.2%2.2%43.0%84.4%240.6%
EPS growth, YoY---24.0%-------
Gross margin56.6%49.1%29.4%34.9%19.3%33.2%34.4%23.9%25.4%-29.6%
Operating margin-163.9%-213.6%-276.1%-205.4%-372.9%-394.7%-234.2%-239.2%-278.9%-396.0%
Net margin-186.6%-158.1%-292.0%-224.9%-374.2%-388.7%-234.6%-240.8%-304.5%-388.4%
Free cash flow margin-116.7%-143.1%-152.1%-174.6%-247.0%-235.7%-209.3%-156.1%-209.2%-327.8%
Return on equity-61.4%-59.4%-102.2%-77.7%-89.7%-104.6%-93.9%-199.5%-399.5%-
Return on assets-37.9%-36.0%-61.7%-52.2%-76.2%-83.2%-72.2%-126.4%-226.3%-281.2%
Current ratio3.762.443.793.393.174.854.392.542.011.00
Debt to equity0.450.400.490.340.00-----

Source: XBRL data DarioHealth Corp. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-18, first reported May 11, 2016; 1-for-20, first reported Mar 17, 2020; 1-for-20, first reported Nov 13, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

DRIO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
DRIO$21.00M-22.6%-$35.67M-169.9%$20.1M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

DRIO FAQ

8 questions
  • What is DRIO revenue?
    DarioHealth Corp. (DRIO) reported $21.00M of revenue for the twelve months ended Jun 30, 2026. That is down 22.6% from the year before. Revenue for fiscal 2025 was $22.36M.
  • Is DRIO profitable?
    No. DarioHealth Corp. reported a net loss of $35.67M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does DRIO have?
    DarioHealth Corp. reported $6.63M in cash and cash equivalents and $31.06M of debt on its most recent balance sheet in SEC filings.
  • How fast is DRIO revenue growing?
    DarioHealth Corp.'s revenue changed -17.3% in fiscal 2025, to $22.36M. Its compound annual growth rate was +24.2% over 5 years and +39.1% over 10 years.
  • What is DRIO gross margin?
    DarioHealth Corp.'s gross profit was $12.21M on $21.00M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 58.2%.
  • What is DRIO free cash flow?
    DarioHealth Corp. generated -$25.48M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$25.34M less capital expenditures.
  • When did DRIO last report financial results?
    The latest statements here come from DarioHealth Corp.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this DRIO financial data come from?
    Quantisnow builds these statements from the structured XBRL data DarioHealth Corp. files with the SEC. It is provided for information only and is not investment advice.